Login to Your Account



Icatibant not Approvable in HAE

Dyax Partners DX-88 with Cubist in Surgery; Awaits Data in HAE

By Jennifer Boggs


Friday, April 25, 2008
In what the company called part of a "multistep commercialization strategy" for DX-88, Dyax Corp. licensed North American and European rights to the intravenous formulation of the compound for use in preventing blood loss during surgery to Cubist Pharmaceuticals Inc. in a potential $231.5 million deal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription